Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Supplementing Corporate Vision, VolitionRx (VNRX) Transitions Chief Medical Officer, Head of U.S. Operations to Full-Time Status

VolitionRx (NYSE MKT: VNRX) is a life sciences company focused on developing simple to use, yet effective diagnostic tests for cancer and other conditions by identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. In recent months the company has made impressive strides toward its goal […]

Moxian, Inc. (MOXC) Announces Launch of New Subsidiary in Beijing

In a news release issued earlier today, Moxian, Inc. (OTCQB: MOXC) announced the formation of a new corporate subsidiary, Moxian Technologies (Beijing) Co. Ltd. The company’s new subsidiary is housed in a nearly 2,000-square-foot office located in Beijing’s Dongcheng district, which is in close proximity to the world-famous Guomao business district. Through Moxian Beijing, Moxian […]

Nutra Pharma Corp. (NPHC) is Doing Things Differently in the Biotech Industry

Nutra Pharma Corp. (OTCQB: NPHC) is introducing new healthcare solutions to the globe. Through ReceptoPharm, a subsidiary, Nutra Pharma is discovering, researching and developing biopharmaceutical products to prevent and/or treat multiple sclerosis (MS), HIV/AIDS, adrenomyeloneuropathy (ADM), herpes, rheumatoid arthritis and pain. Drug Discovery & Development Nutra Pharma is in the business of acquiring, licensing and […]

 

From Our Blog

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones

July 28, 2026

Cartilage Regeneration Gains Strategic Validation The orthopedic industry is increasingly focused on technologies that can address cartilage damage by promoting tissue regeneration rather than simply managing symptoms. This opportunity gained additional validation when Smith+Nephew completed its acquisition of CartiHeal, a developer of cartilage repair technology, in a transaction valued at up to $330 million. The […]

Rotate your device 90° to view site.